Notch signalling and the downstream effector HES1 is required for multiple pancreatic cell fate choices during development, but the direct target genes remain poorly characterised. Here we identify direct HES1 target genes on a genome-wide scale using ChIP-seq and RNA-seq analyses combined with human embryonic stem cell (hESC) directed differentiation of CRISPR/Cas9generated HES1 −/− mutant hESC lines. We found that HES1 binds to a distinct set of endocrinespecific genes, a set of genes encoding basic Helix-Loop-Helix (bHLH) proteins not normally expressed in the pancreas, genes in the Notch pathway, and the known HES1 target NEUROG3.
Introduction
Stem cell-based regenerative therapy for Type I Diabetes has the potential to prevent secondary complications and relieve patients from cumbersome blood glucose measurements multiple times per day by providing transplantable, in vitro differentiated insulin-producing β-cells. Recent years has brought great advances in protocols to produce β-like-cells from human embryonic stem cells (hESCs), largely based on knowledge from pancreas development in the mouse and other model organisms. In vitro differentiation of hESCs into β-like-cells also presents an opportunity to study a simplified, scalable and accessible model of human pancreas development.
The mouse pancreas epithelium consists of three tissue types, enzyme producing acinar cells, hormone producing endocrine cells of the islet of Langerhans and duct cells lining the ductal tree that connects to the small intestine. These parenchymal cells all stem from a common multipotent progenitor cell (MPC) population, marked by co-expression of a signature set of transcription factors; Pdx1, Nkx6-1, Ptf1a and Sox9. Later, the MPCs segregate into Ptf1a + tip-and Sox9 + Nkx6-1 + trunk progenitors under the influence of a mutually repressive interaction between Ptf1a and Nkx6-1 and instructed by Notch signalling (Afelik et al., 2012; Horn et al., 2012; Shih et al., 2012) .
Endocrine cells arise from an intermediary precursor stage marked by Ngn3 expression (Apelqvist et al., 1999; Gradwohl et al., 2000; Gu et al., 2002; Jensen et al., 2000a; Schwitzgebel et al., 2000) .
The first endocrine cells emerge from MPCs through and are mainly α-and ε-cells, while β-, δ-, and γ-cells arise later from the trunk epithelium (Heller et al., 2004; Johansson et al., 2007; Prado et al., 2004) . We and others have shown that loss of Hes1 as well as other Notch pathway genes leads to excess endocrine differentiation (Apelqvist et al., 1999; Fukuda et al., 2006; Jensen et al., 2000b; Sumazaki et al., 2004) . Thus, formation of endocrine cells is negatively regulated by Notch such that low Notch activity and thereby low Hes1 levels relieve Neurog3 repression and allow high levels Neurog3 protein and thereby commitment to the endocrine lineage, Neurog3 is expressed only transiently (Bankaitis et al., 2015; Gradwohl et al., 2000; Gu et al., 2002; Jensen et al., 2000a) while located in the progenitor epithelium after which the differentiating endocrine cells, now expressing Neurog3 target genes such as Neurod1 and Insm1, delaminate from the epithelium and coalesce into the islets of Langerhans as single hormone producing α-, β-, γ-, δ-and ε-cells (Gasa et al., 2004; Gradwohl et al., 2000; Jensen et al., 2000b; Schwitzgebel et al., 2000) .
Notch signalling thus plays a pivotal role in pancreas cell fate choice, but little is known about how Notch and its main effector Hes1 regulates pancreas development on a molecular level. Generally, Notch signalling is activated by Delta/Jagged-family ligands that bind Notch receptors on a neighbouring cell inducing a series of proteolytic cleavages the last of which is by the ɣ-secretase complex. This leads to translocation of the Notch intracellular domain to the nucleus, where it acts in complex with Rbpj and Maml1 to activate transcription (Bray, 2006) . Prominently among the target genes activated by Notch in the pancreas is Hes1, encoding a bHLH-protein that itself binds to specific regulatory sites on DNA and recruits Groucho/TLE proteins to form a repressive complex (Kageyama et al., 2007) . Only a few Hes1 target genes are described in the pancreas, including Neurog3 and Cdkn1c, encoding p57 Kip2 (Georgia et al., 2006; Lee et al., 2002) . Notably, in several tissues including presomitic mesoderm and neural progenitors, but not yet described in the pancreas, Hes1 binding to its own promoter results in auto-repression and oscillatory expression of the protein as well as of some of its target genes (Hirata et al., 2002; Kobayashi et al., 2009a; Sasai et al., 1992; Takebayashi et al., 1994) . Other examples of negative feedback in the Notch pathway includes lateral inhibition with its associated suppression of ligand expression in cells that receive Notch signalling, typically as a consequence of Hes-mediated repression of bHLH family transcriptional activators that activate ligand expression in the absence of Notch (Bray, 2006) .
Recent work demonstrates that many of the same transcription factors are found in the human embryonic pancreas, and in much the same patterns (Jennings et al., 2017; . However, since the fetal development of humans compared to mice is much longer and due to the scarcity of human fetal material from early stages it is unclear whether there is a clear equivalent to the primary/secondary transition stages seen in rodents and whether Notch signalling plays a similar role in human development as in mouse. Nevertheless, most hESC protocols aimed at generating β-like-cells successfully employ γ-secretase inhibitors to induce endocrine differentiation indicating that Notch signalling is active in hESC-derived pancreas progenitors. Moreover, recent work from one of us revealed that CRISPR/Cas9-mediated HES1 null mutations in hESCs cause increased formation of C-peptide + cells (Zhu et al., 2016) , bolstering the case for Notch-mediated regulation of pancreatic endocrine development in humans also.
Here we take advantage of the ease at which pancreatic progenitors can be produced from hESCs to define direct HES1 target genes on a genome-wide scale and thereby uncover novel functions for HES1 in pancreatic development. We identify genomic HES1 binding sites by chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) and compare bound genes to genes that are deregulated by CRISPR/Cas9-induced loss of HES1. Additional deletion of HES1 on a NEUROG3-null background enabled us to assess genes deregulated by loss of HES1 independently of the endocrine programme initiated by NEUROG3. Thereby we uncovered a subset of endocrinespecific transcripts that are regulated in opposite directions by NEUROG3 and HES1 and show derepression in HES1 −/− NEUROG3 −/− double-null cells. We also unravel a direct repression of Notch ligand genes DLL1 and DLL4 by HES1. A number of HES1 bound distal regulatory elements map to known FOXA2 binding sites suggesting co-occupancy with FOXA2. Remarkably, these targets include lineage specific genes that are not expressed in the pancreas. Among the direct, deregulated target genes are classic HES1 target genes from other organ systems such as ATOH1 and ASCL1. Together, our data suggest a multi-layered mechanism for HES1 suppression of pancreatic endocrine development and additionally serves to suppress inappropriate expression of a set of non-pancreatic bHLH factors.
Results
Generation of HES1 and NEUROG3 mutant cell lines.
To better understand the mechanism by which HES1 regulates pancreas development we took advantage of recent developments in directed differentiation of human embryonic stem cells (hESCs) to the pancreatic endocrine lineage via a series of progenitor stages (Figure 1 and (Rezania et al., 2014) . Using the iCRISPR platform (González et al., 2014) , we introduced indels in the HES1 and NEUROG3 genes, either singly or in combination in iCRISPR H1 cells.
Using previously described gRNAs (Zhu et al., 2016) to target exon2 of the NEUROG3 gene and exon2 of the HES1 gene we detected by Sanger and RNA-sequencing a GA insertion and a T insertion, respectively, resulting in premature STOP codons ( Figure 1A and Sup. Figure 2) . We confirmed the loss of HES1 protein by western blotting (Figure 1A ,B) in two/multiple clonal cell lines carrying the introduced mutation and the loss of NEUROG3 by immunostaining ( Figure 1B and Figure 2 ). We then subjected two or more clonal lines of H1-iCRISPR (wildtype), HES1 −/− , NEUROG3 −/− and HES1 −/− NEUROG3 −/− (abbreviated H1N3-dKO or H1 −/− N3 −/− ) to differentiation to β-like cells using a modified version of the protocol from Rezania et al. (2014) . Marker analysis showed that all celllines maintained pluripotency (OCT4 + ) as hESC and were able to differentiate to FOXA2 + and SOX17 + co-positive definitive endoderm (DE, Day 3), PDX1 + cells at the posterior foregut stage (PF, Day 7), to bipotent progenitors marked by PDX1 + and NKX6-1 + at the Pancreatic Endoderm stage In a previous report, one of us showed an excess of C-peptide expressing cells at the polyhormonal-β stage in differentiated HES1 −/− cell lines (Zhu et al., 2016) consistent with a repressive role for HES1 on endocrine differentiation (Jensen et al., 2000b) . Assessing the timing of endocrine commitment in more detail allowed us to extend the previous observation and demonstrate precocious NEUROG3 + cells in the HES1 −/− cell lines as early as Day 7 at the PF stage, similar to the precocious appearance of these cells in the E8.5 mouse embryo (Ahnfelt-Rønne et al., 2012; Jensen et al., 2000b) . At the Day 10 PE-and Day 13 EP-stages, we observed a prominent increase of NEUROG + cells in the HES1 −/− cell lines compared to wildtype while they were absent from the NEUROG3 −/− and HES1 −/− NEUROG3 −/− cell lines as expected ( Figure 2 and Sup. Figure 7 ). C-peptide and glucagon single-positive cells were observed already at Day 10 and more prominently at Day 13 in the HES1 −/− cells, demonstrating very early differentiation to monohormonal α-and β-like cells (Figure 2 and Sup. Figure 7 ). This is also apparent by RT-qPCR, where GCG, INS, and NEUROD1 expression was markedly increased in HES1 −/− samples at both Day 10 and 13 compared to wildtype and with undetectable levels in the NEUROG3 −/− cell lines (Sup. Figure 8 ). In contrast to some of our previous work by Zhu and co-workers who saw around 0.5% C-peptide + cells in Day 20 PH-β stage NEUROG3 −/− HUES-8 cells (Zhu et al., 2016) , in present study we did not detect C-peptide by immunocytochemistry in NEUROG3 −/− H1 cells at the PH-β stage, however in the HES1 −/− NEUROG3 −/− H1 cells they were present at a low frequency ( Figure 2 ).
RNA-sequencing reveals NEUROG3-dependent and -independent changes in the HES1 − /− transcriptome To study the genome-wide transcriptional changes occurring upon loss of HES1 we performed RNA-sequencing (RNA-seq) on two differentiation experiments with two cell lines of each genotype on Day 13. Principal Component Analysis ( Figure 3A ) revealed that the samples and experiments cluster according to genotype and that HES1 −/− differs most from the other genotypes at this stage. We did differential expression analysis at the gene level using DESeq2 and found 1198 genes are significantly differentially expressed and upregulated in HES1 −/− cells compared to wildtype controls with an adjusted p-value ≤0.1 and log2 fold change ≥ 1.5. Similarly, we find 482 Figure 3C ).
Deregulation of endocrine lineage genes
To comprehend the differences in expression between the genotypes we did k-means clustering analysis on all genes that are deregulated in any comparison and this revealed succinct expression patterns for each genotype. Genes that are highly expressed in HES1 −/− compared to the other genotypes are clustered in group 1 and 2, and as expected they include peptide hormone genes such as INS, GLU, SST, GHRL, and PYY as well as numerous genes encoding endocrine-specific transcription factors such as NEUROG3, NEUROD1, NEUROD4, PAX4, PAX6, INSM1, and ISL1. Next, we performed Gene Set Enrichment and found in the HES1 −/− vs wildtype the top three datasets to be a very strong enrichment of the gene signature from "glucagon producing α-cells" (Normalised Enrichment Score, NES 6.62), "Oxididative phosphorylation" from the KEGG database and a gene signature of "Enteroendocrine cell" (Sup. Figure 6 ). Emphasising that the HES1 −/− cells strongly differentiate towards the endocrine lineage.
Interestingly, in a parallel analysis in HES1 −/− NEUROG3 −/− vs. NEUROG3 −/− also found the signature "Alpha-cells", showing that a significant set of genes expressed in α-cells are upregulated in the HES1 −/− NEUROG3 −/− despite the loss of NEUROG3 (Figure 3 ), suggesting HES1 regulates certain endocrine lineage genes independently of NEUROG3. Remarkably, the "Goblet cell" signature from the intestinal system was also highly enriched driven by a number of goblet cell markers such as GFI1, TFF3, KLF4 and ATOH1.
Deregulation of Notch pathway genes Notably, we find several genes encoding Notch pathway components among the genes that are deregulated by loss of HES1. Most significantly, the ligand-encoding genes DLL1 and DLL4, as well as NEURL1, encoding an E3 ubiquitin ligase with several Notch ligands among its substrates (Koutelou et al., 2008) and MFNG, which encodes a glycosyltransferase that extends O-fucose moieties on Notch receptors (Kakuda and Haltiwanger, 2017) Remarkably, among the deregulated genes that are known targets of the Notch pathway we find not only genes expected to be expressed in the pancreas but also some that are not normally expressed in the pancreas. For example, we find significantly higher levels of ASCL1, ASCL2 and ATOH1, transcripts that encode bHLH factors that are not expected to be expressed in the pancreas epithelium, in HES1 −/− NEUROG3 −/− compared to wild type or NEUROG3 −/− cell lines and confirmed for ASCL1 by RT-qPCR (Sup. Figure 8 ). Interestingly, HES1 mRNA remains unchanged in all genotypes despite the frame-shift mutation which would often lead to non-sense mediated decay, however, the potential loss of repression by HES1 protein on its own promoter could compensate by increasing gene expression (Takebayashi et al., 1994) (Kobayashi et al., 2009b; Sasai et al., 1992) . NEUROG3 mRNA levels are noticeably lower in the NEUROG3 −/− lines, but wild type levels are restored in the HES1 −/− NEUROG3 −/− cell lines (Sup. Figure 8 ).
HES1 does not regulate cell cycle genes HES1 has been associated with regulation of the cell cycle through direct repression of the CDK inhibitor p57 KIP2 (encoded by CDKN1C) (Georgia et al., 2006) . However, we do not see HES1 binding to this gene, nor do find CDKN1C to be significantly deregulated between NEUROG3 −/− and HES1 −/− NEUROG3 −/− , suggesting that it is not a direct target gene (Sup. Figure 3 ) . Only in the HES1 −/− samples is it upregulated compared to wild type pointing towards an indirect regulation of the gene, in that many cells enter a post-mitotic endocrine cell fate after loss of HES1. Also, we examined other well-studied proliferation markers such as PCNA and MKI67 and found them to be downregulated only in the HES −/− samples (Sup. Figure 3C ). Assessing all cell cycle associated genes (GO term Cell Cycle) we found many to be deregulated after loss of HES1, but not in the HES1 −/− NEUROG3 −/− cells. The few genes that are actually deregulated and in the GO term Cell Cycle are to our knowledge are not controlling cell cycle but are expressed in cell types that are generally not cycling, such as NEUROD1 and INSM1 in endocrine cells. Others such as CDK5R2 is an activator of the atypical cyclin kinase CDK5 and not regulating normal cell cycle (Martin et al., 2012) .
ChIP-seq identifies direct HES1 target genes
To identify genome-wide, direct targets of HES1 in human pancreas progenitors, we performed Chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) of endogenous HES1 in the HUES4 PDX1 GFP/+ reporter cell line on Day 13 of differentiation from both unsorted bulk populations and FACS-sorted GFP + cells. Peak finding by MACS2 revealed 998 peaks shared between the two replicates of unsorted Day 13 cells, distributed with 744 peaks near promoters, defined by 2kb upstream or 0.5kb downstream of transcription start sites (TSS), and 254 at distal sites (non-TSS). Motif search on 200bp around the summit of the 744 peaks close to TSS revealed an extended motif similar to the previously described HES/Hairy binding sites, the N-Box and the Class C site (Ohsako et al., 1994) : a SGCRCGYGC motif which was contained in 64% of the peaks, indicated with red marks in Figure 4 . Motifs are often found close to the peak centre such as for DLL1 locus, but there are also matching motifs in the near vicinity of peaks, apparently not bound by HES1, suggesting other co-factors and the epigenetic environment determines the binding.
NEUROG3 is an example of a bound gene which does not contain the full HES1 motif but does contain the core motif of the class C site: cgcCACGCGag.
Surprisingly, at the distal sites (non-TSS) we found a motif belonging to FOXA-family of transcription factors to be the most enriched, not the expected HES1 motif. HES1 has to our knowledge not previously been associated with FOXA2 and we took advantage of our previously published FOXA2 ChIP-seq data (Weedon et al., 2014) to show an abundance of FOXA2 localised to a subset of the non-TSS peaks but not to the peaks located close to TSS.
Identification of HES1 bound genes that are also deregulated in HES1 −/− NEUROG3 −/− compared to NEUROG3 −/− samples yielded 28 genes that are de-repressed ( Figure 5 ). The mean expression across genotypes are shown as a heat map in Figure 5C , which reveals several genes expressed in the endocrine lineage and previously described to be downstream of NEUROG3, including DLL1, DLL4, MFNG, NEUROD1, MNX1, INSM1 and NEUROG3 itself (Gradwohl et al., 2000) (Schwitzgebel et al., 2000) (Jensen et al., 2000a) (Gasa et al., 2004) , which are all upregulated in D13 EP stage HES1 −/− NEUROG3 −/− cells in spite of the absence of NEUROG3. Although DLL1 is likely not to be endocrine-specific (Ahnfelt-Rønne 2012), these data nevertheless show that loss of HES1 is sufficient to promote the expression of a number of genes expressed specifically in the endocrine lineage independently of the presence of NEUROG3 protein. This unexpected finding is revealing that HES1 represses endocrine lineage determination at multiple levels.
A number of genes, including PAX6, CCK, and DUSP4 are upregulated in HES1 −/− cells compared to wildtype, but not in HES1 −/− NEUROG3 −/− cells compared to NEUROG3 −/− samples, suggesting that activation of these genes depends strictly on NEUROG3. Given that they are bound by HES1 it is possible that they also depend on HES1 being downregulated, but that it is not sufficient.
Unfortunately, our current experimental setup does not allow us to test for this.
Several genes containing FOXA2 and HES1 bound sites are not normally expressed in pancreatic tissue. These include homeobox genes such as CDX2 and ISX as well as bHLH genes such as ASCL1, which are expressed in other endodermal organs like the intestine or, in the case of ASCL1, the lungs and stomach. Both ISX and ASCL1 are upregulated in HES1 −/− compared to wild type samples and also in HES1 −/− NEUROG3 −/− compared to NEUROG3 −/− samples, suggesting that HES1 may prevent inappropriate expression of these genes in the pancreas (Error! Reference source not found.).
Lastly, we compared our HES1 ChIP-seq data to the previously published ChIP-on-CHIP of Hes1 in mouse embryonoic stem cells from the Kageyama lab (Kobayashi et al., 2009b ) by liftover of the reported peak to the human genome (hg19) and found HES1 enrichment on half of the reported top 50 peaks (Sup. Figure 4 ). This observation shows a remarkable conservation of HES1/Hes1 binding across species and interestingly also cell types, highlighting the relevance of present HES1 binding studies for other systems.
Discussion
Here we have uncovered novel functions of HES1 in pancreas development and unravelled a multilayered mechanism that secures robust regulation of pancreatic endocrine development. Our work highlights the importance of understanding the transcription factor networks that are regulating human β-cell differentiation and for development of efficient and precise protocols that enable the generation of β-like-cells suitable for diabetes therapy. Taking advantage of recent advances in protocols for deriving β-like-cells from hESCs (Pagliuca et al., 2014; Rezania et al., 2014) we used the iCRISPR platform to induce mutations in the HES1 and NEUROG3 genes in order to understand the molecular mechanisms of HES1-regulated pancreatic cell fate decisions.
Consistent with a previous report on the HUES4 cell lines (Zhu et al., 2016) , the H1-iCRISPR HES1 −/− cell lines exhibit excessive endocrine differentiation, and in line with previous publications in mice, we find precocious appearance of the early endocrine progenitor marker NEUROG3 at Day 7 and of c-peptide and glucagon as early as Day 10 on both protein and mRNA level (Ahnfelt-Rønne et al., 2012; Jensen et al., 2000b) . Beyond single markers we used GSEA to assess enrichment of gene signatures in HES1 −/− cells and as expected found genes expressed in α-cells as defined by single cell RNA-sequencing experiments (Segerstolpe et al., 2016) as well as Oxidative Phosphorylation from the KEGG database.
While expected, the huge shift in cell fate, towards endocrine differentiation, that is provoked by HES1 deficiency prevented the identification of genes that potentially were deregulated specifically in the progenitor population, where HES1 is active. We therefore used a "biological filter" to avoid the massive secondary transcriptional changes associated with the endocrine lineage choice by taking advantage of the impaired endocrine differentiation of NEUROG3 null cells and compared HES1 −/− NEUROG3 −/− double knockout-to NEUROG3 −/− single knockout cells, which allowed us assess NEUROG3 independent HES1 target genes. A similar approach has previously been used in the Shivdasani lab to "filter out" specific intestinal cell populations (Kim et al., 2014) .
We analysed potential changes in cell cycle regulation. Hes1 has previously been proposed to regulate the cell cycle in embryonic mouse pancreas through binding to an E-box in the Cdkn1c gene and thereby directly repress p57 Kip2 expression (Georgia et al., 2006) , and others have suggested that sustained expression of Hes1 inhibits cell cycle progression through repression of PCNA, E2F1, and CDKN1A (encoding p21 CIP1 ) (Baek et al., 2006; Castella et al., 2000; Georgia et al., 2006; Hartman et al., 2004; Hatakeyama, 2004; Murata et al., 2005; Ström et al., 2000) . However, although we did observe increased CDKN1C expression in the HES1 −/− cells compared to wildtype, we observed no change when comparing HES1 −/− NEUROG3 −/− to NEUROG3 −/− cells, suggesting indirect activation of CDKN1C in endocrine committed cells downstream of NEUROG3 and not a direct effect of HES1 deficiency. Consistent with this notion, we did not observe HES1 binding to the CDKN1C gene in our ChIP-seq data. Similarly, the decrease in PCNA and MKI67 expression argues against HES1-mediated repression of these genes. Indeed, PCNA and MKI67 expression was restored in HES1 −/− NEUROG3 −/− cells suggesting that this pattern can be explained simply by the increased proportion of post-mitotic NEUROG3 + and PAX6 + cells, and the associated depletion of proliferating PPs seen in our Day 13 HES1 −/− hESC-PP cultures.
From our HES1 ChIP-seq data, which is to our knowledge the first high quality ChIP-seq analysis of endogenous HES1, we identified 998 high confidence peaks. De novo motif search yielded the sequence "SGCRCGYGC", which contains the Class C Hairy binding site in the majority of the peaks located close to a TSS (Ohsako et al., 1994; Sasai et al., 1992; Takebayashi et al., 1994) .
Unexpectedly, we found a FOXA motif as the most enriched on distal regulatory elements, and an analysis of FOXA2 ChIP-seq data from hESC-PPs previously published by one of us (Weedon et al., 2014) , revealed FOXA2 binding close to many of these HES1 peaks. It is possible that FOXA2, a known pioneer factor (Iwafuchi-Doi et al., 2016) , acts to open the chromatin allowing HES1 to access its binding sites. It should be stressed however that we cannot be certain that co-binding occurs in individual cells. Nevertheless, many of the genes bound by both HES1 and FOXA2 are part of complex transcription factor networks that regulate cell fate in other endodermal tissues.
This includes CDX2, ISX in the intestines and ASCL1 in the stomach and lungs (Imayoshi et al., 2013; Ito et al., 2000; Jensen et al., 2000b; Kobayashi et al., 2009b; Kokubu et al., 2008) and it is likely that expression of such genes would interfere with normal pancreas development. In our hESC-PP cultures it is noteworthy that intestinal markers such as IHH and VIL1 are induced, albeit modestly, by loss of HES1, in both wildtype and NEUROG3 deficient background, suggesting a shift towards intestinal fate (Error! Reference source not found.).
Previously, the Kageyama lab published a ChIP-on-chip analysis of Hes1 binding sites in mouse embryonic stem cells (Kobayashi et al., 2009b) . By comparison we found half of the reported peaks (top 50) to be enriched for HES1 on the corresponding site by doing lift-over from mouse genome (mm7) to human genome (hg19) (Sup. Figure 4 ). This shows conserved binding across species and strikingly across cell types suggesting HES1 binds many of the same genes independent of cellular context but rather that additional repressors and activators decide the contextual output. Among the Hes1/HES1 target genes shared between hESC-PPs and mESCs is Hes1/HES1 itself. As shown in Figure 4 , we observe HES1 binding to several sites in its own promoter suggesting that, similar to many other tissues, HES1 may regulate its own promoter activity in a negative feedback loop in pancreas progenitors. This negative feedback is key to ultradian oscillations in Hes1 promoter activity and Hes1 protein expression observed in mouse embryos in presomitic mesoderm as well as in neural progenitors (Hirata et al., 2002; Shimojo et al., 2008) . We are currently investigating whether ultradian oscillations are a feature of pancreatic Hes1 expression and function.
Knock-out of HES1 on a NEUROG3-null background yielded 482 de-repressed genes (>1.5 log2FoldChange) of which 28 genes contained identified HES1 ChIP-seq peaks, these genes included an array of endocrine markers such as NEUROD1 and INSM1, two key transcription factors previously thought to be downstream of NEUROG3. PAX6, encoding another well described endocrine transcription factor, is also bound by HES1, but its expression appears to depend strictly on NEUROG3. It his appears that HES1 regulates endocrine differentiation by repressing the key endocrine-inducing TF NEUROG3 as well as some of its target genes, a certain subset of which depends on HES1 activity in order not to become prematurely expressed. HES1 thus employs a multi-layered mechanism to regulate endocrine differentiation.
HES1 bound and regulated several Notch pathway genes, including the ligand encoding genes (Gasa et al., 2004; Lacomme et al., 2012; Treff et al., 2006) , but we show here that DLL1 and DLL4 are not only bound by HES1, but also derepressed when HES1 is deleted. Crucially, derepression was also observed in the absence of NEUROG3 suggesting that other transcription factors are responsible for their activation. Consistent with this notion, DLL1 and DLL4 were recently found to be bound by SOX9 and PDX1 in hESC-PPs (Shih et al., 2015; Wang et al., 2018) .
We also find the E3 ubiquitin ligase NEURL1 to be upregulated in the HES1 −/− NEUROG3 −/− . NEURL1
is an ortholog of Drosophila Neuralized which is necessary for Notch ligand activation in flies, but its function in mammals is not well understood as, in contrast to the fly, Neurl1 −/− and Neurl1/2 double knockout mice are viable and fertile with only minor phenotypes (Koo et al., 2007; Ruan et al., 2001; Vollrath et al., 2001) . Further investigations are needed to determine if NEUROG3 directly regulates Notch ligands in the pancreas or if lateral inhibition is determined by HES1-Delta/Jagged-Notch feedback loops only. Importantly, we also show HES1 binding to the NEUROG3 promoter and that loss of HES1 is sufficient to activate NEUROG3 expression in hESC-PPs even without the auto-activating effect of NEUROG3 previously proposed to drive cells from a NEUROG3 Lo to a NEUROG3 Hi state in mice and in vitro (Ejarque et al., 2013; Gasa et al., 2004; Wang et al., 2008) . Some of us has previously shown that some NEUROG3-independent endocrine cells are formed (~0.5% C-peptide + ) by FACS analysis in the HUES4 iCRISPR NEUROG3 −/− cell line (Zhu et al., 2016) , However, in the present study on the H1 hESC background we do not observe this by immunostaining, in line with other studies on NEUROG −/− cells assessed by immunostaining (McGrath et al., 2015) . Neurog3 knock-out mice were first described to be devoid of any endocrine cells but additional knock-out alleles on different mouse backgrounds have revealed small numbers of endocrine cells despite the loss of Neurog3 suggesting additional mechanisms to turn on the endocrine programme (Gradwohl et al., 2000; Wang et al., 2008) . Also, occasional glucagon + cells are observed in Dll1 −/− Neurog3 −/− and Hes1 −/− Neurog3 −/− mouse embryos (Ahnfelt-Rønne et al., 2012; Jørgensen et al.) . Consistent with such mouse data, we observe some NEUROG3-independent endocrine cells in the HES1 −/− NEUROG3 −/− , indicating that HES1 could additionally de-repress other factors capable of driving endocrinogenesis although at a very low frequency. In zebrafish the ASCL1-ortholog ascl1b, rather than neurog3 control pancreatic endocrine cell fate, indicating that other bHLH factors such as ASCL1 or ATOH1 which are highly upregulated in the HES1 −/− NEUROG3 −/− could potentially drive endocrine cell fate choice, as they do for stomach and intestinal endocrine cells, respectively (Flasse et al., 2013; Kokubu et al., 2008; Yang et al., 2001) . Similar observations in vivo and lineage tracing experiments would be necessary to prove such plasticity of bHLH factors in the pancreas which was previously described in a neuronal system (Parras et al., 2002) . Remarkably, ASCL1 and ATOH1 expression was much higher in HES1 −/− NEUROG3 −/− cells than in HES1 −/− cells, showing that NEUROG3 is repressing expression of these two genes. B-class bHLH factors have previously been implicated in repressing each other's expression. For example, Atoh1 and Neurog1 mutually inhibit expression of the other factor in the brain (Gowan et al., 2001) and Ascl2 blocks the myogenic activity of MyoD in muscle satellite cells by occupying MyoD binding sites in a non-productive fashion (Johnson et al., 1992) (Wang et al., 2017) .
We find a "Goblet cell" signature enriched in the HES1 −/− NEUROG3 −/− expression dataset by GSEA analysis including the HES1 bound gene ATOH1 which is required for goblet cell formation in the intestine (Yang et al., 2001) , which is in line with Notch loss of function mouse models Hes1 -/-, Rbpj -/and Dll1 -/-Dll4 -/where Atoh1 is upregulated in the intestine leading to an increase in goblet cells (Jensen et al., 2000b; Pellegrinet et al., 2011) . Furthermore, Notch overexpression in the intestine, and thereby sustained Hes1 leads to a failure to form goblet cells ((Fre et al., 2005; van Es et al., 2005) ). Remarkably, expression of goblet cell markers is further increased in HES1 −/− NEUROG3 −/− cells compared to HES1 −/− cells, and it is noteworthy that ectopic goblet cell formation is observed in the stomach of Neurog3 −/− mice. However, there has been no reported increase in goblet cell numbers in neither Neurog3 −/− nor Hes1 −/− pancreas. Although they receive little attention, mouse pancreatic ducts do contain mucin-producing goblet cells in addition to the classical bicarbonate-secreting principal cells (Lev and Spicer, 1965) . These goblet cells are likely differentiating from the trunk progenitors, which then should be considered tri-potent rather than bi-potent. We hypothesise that upon low Notch activity a tri-potent progenitor would allow Atoh1 
Materials and Methods
Generation of knock-out human embryonic stem cell lines H1 human embryonic stem cell lines with a doxycycline inducible Hygro-iCRISPR-Cas9 (iCRISPR) Wildtype (clone E8) and H1 Hygro-iCRISPR NEUROG3 −/− (clone N6_H3) were generated by Z. Zhu and D. Huangfu, Columbio University, similarly to previously described in HUES8 human embryonic stem cell line (González et al., 2014; Zhu et al., 2016) .
Cells were maintained in the E8 media on human recombinant Vitronectin (ThermoFisher) according to manufacturer's instructions changing media every day and splitting 1:10 using Versene (ThermoFisher) to dissociate for 5-7min, removing the Versene and lifting cells with fresh media by pipetting. Gel purified PCR-product was diluted to 100nM for T7 IVT reaction using MEGAshortScript T7 Transcription kit (ThermoFisher): 2 µL reaction buffer, 8µL dNTPs, 1µL dsDNA template, 2µL enzyme, 7µL H 2 O. After 4h incubation at 25°C, added DNAse 15min 37°C and purified with RNeasy Micro kit (Qiagen) to a concentration about 1µg/mL stored at -80°C. To evaluate transfection efficiency by microscopy, we also made a gRNA with Cy3-flourescence labeled dCTP, however the cells transfected with these was not used for further work.
Wildtype and NEUROG3 H1 hygro-iCRISPR cell lines were treated with doxycycline (1µg/mL) for 48 hours prior to transfection. Cells were washed twice with PBS and dissociated with TrypLE Select (ThermoFisher) for 5 minutes, diluted in media and spun down 4 min 200g. Resuspended in 1mL of media. Seeded 800.000 cells/well 1.5mL media in a 6-well. Made 150µL OptiMEM (ThermoFisher) with 9µL RNAiMAX (ThermoFisher) and mixed with 150µL OptiMEM with 1µg gRNA, incubated 5min and dropped on the cells. Changed every day and split cells three days after transfection to clonal density, around 2000 cells per 10cm plate. Used approximately 1/5 of the leftover cells for transfection efficiency genotyping: pelleted cells, removed media, added 20µL QuickExtract (EpiCentre) and incubated >3h at 65°C, then stopped the reaction at 95°C 15min. and diluted 1:10 for PCR reaction. PCR reaction was setup using Phusion HighFidelity MasterMix (NEB) 5µL, 1µL 10µM mix of primers Fwd: CGGATAAACCAAAGACAGCA and Rev: CATAGAGTAGGCAAGAAAGGA, 3% final volume DMSO, 2.7µL H 2 O and 1µL DNA. 98°C 4 minutes, 34 cycles of 98°C 30 sec., 60.8°C 30 sec., 2 min 72°C and then a final extension at 72°C 10 minutes. PCR reaction run on an agarose gel to check band size and purity and then gel purified with Centrifugal Unit for Gel Extraction (Millipore) and subsequently purified using DNA Clean and Concentrator-5 (Zymo) and eluted in 8µL. 5µL eluted PCR product with 5µL 5µM sequencing primer(TGTATCTCTTTGCAGCCCCT) was sent for Sanger Sequencing at GATC Biotech. CRISPR-Cas9 efficiency was estimated using TIDE software (https://tide.deskgen.com) (Brinkman et al., 2014) to be up to 65% indel formation.
Picked the number of clones accordingly, 10 days after clonal seeding in PBS to an 1.5mL tube containing 50µL versene for dissocation. Took approximately half for seeding in a 24-well and the other half for clonal PCR by same protocol as for the transfection efficiency PCR. Using TIDE software to estimate the genotype, skipping everything that potentially could be heterozygous and Topo-cloned the PCR product of the putative knock-out clones. Sanger-sequenced >6 Topo-Clones for each hES-clone and evaluated validity of the genetic knock-out also by western blot. exp.), 12, 28 were seeded in Ibidi slides as explained above.
HES1 −/−
For 48 hours prior to differentiation cells were kept in E8 hESC media changing media every day also for differentiation. The protocol is slightly modified version from the Kieffer Lab (Rezania et al., 2014) including porcupine inhibitor IWP-6 at 5µM for days 3-6. Compounds and solutions are from ThermoFisher unless otherwise stated. were added to make up Stage 1 (S1) media with the addition of CHIR and Activin A according to below tables for 2 days (t=0, t=24h) , and for the 3 rd day not adding CHIR, but only Activin A(t=48h).
For Stage 2 (S2) in the same basal media according to below scheme S2 Media to get Primitive Gut Tube (GT). See also scheme in (Figure 1) Reads from the Nextseq were converted to FASTQ-files using bcl2Fastq (Illumina) on Computerome high performance cluster, were also FASTQC quality control and alignment to hg38 human genome with STAR was done (Dobin et al., 2013) with standard settings resulting in >90% alignment of reads. Loaded the gene count table into DESEQ2 for differential expression analysis on gene level (Love et al., 2014) . With the DESEQ2 package in R we performed quality control assessment by Principal Component Analysis after regularized logarithmic transformation. For the differential expression analysis we did Log-Fold-Change shrinkage with DESEQ2 and tested genes deregulated in at least one of these comparisons, used for the graphs in (Figure 3 ).
S1-S2 basal media
Using the org.Hs.eg.db for annotation and EDAseq packages gene lengths we obtained gene length normalised read counts (FPKM), which is useful for comparing absolute expression levels across genes. For plotting ggplot was mostly except for heatmaps and kmeans clustering (centers=5) for which superheat package was used with manhattan distance measure and ward.D2 method.
Gene Set Enrichment Analysis was done with KEGG database, transcriptomics form our own lab described below and gene sets from recent publications using single cell RNA-sequencing to find markers exclusively expressed in specific cell types in order to establish a database of 42 cell types from human pancreas, mouse intestine (lifted to human) and neuronal cell types (Haber et al., 2017; La Manno et al., 2016; Segerstolpe et al., 2016) . Overview of database genesets from outside sources. We also employed datasets form our own lab, including genes up-and downregulated on RNA-seq from FACS sorted GFP + cells from E10.5 Hes1 +/+ Pdx1 GFP/+ and The reporter cell line was seeded on Fibronectin at cells/cm 2 and followed the differentiation protocol as described above. On Day 13 cells were dissociated with TrypLE and For overlap of HES1 ChIP-seq peaks and RNA-seq expression data the gene name was used, recognising all the HES1 associated genes. 
Figure Legends

